AMEX:PTN

Stock Analysis Report

Executive Summary

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States.


Snowflake Analysis

Flawless balance sheet with outstanding track record.

Share Price & News

How has Palatin Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PTN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.8%

PTN

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

-29.8%

PTN

14.0%

US Biotechs

17.9%

US Market

Return vs Industry: PTN underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: PTN underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

PTNIndustryMarket
7 Day1.8%0.7%-1.1%
30 Day-15.2%5.6%1.4%
90 Day-28.4%6.2%6.9%
1 Year-29.8%-29.8%14.9%14.0%20.3%17.9%
3 Year58.2%58.2%24.4%21.1%47.8%38.3%
5 Year-37.2%-37.2%3.8%-1.0%71.9%53.0%

Price Volatility Vs. Market

How volatile is Palatin Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Palatin Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PTN ($0.59) is trading below our estimate of fair value ($3.6)

Significantly Below Fair Value: PTN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PTN is good value based on its PE Ratio (3.6x) compared to the Biotechs industry average (20.1x).

PE vs Market: PTN is good value based on its PE Ratio (3.6x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: PTN's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: PTN is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Palatin Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-6.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTN's earnings are forecast to decline over the next 3 years (-6.3% per year).

Earnings vs Market: PTN's earnings are forecast to decline over the next 3 years (-6.3% per year).

High Growth Earnings: PTN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PTN's revenue is expected to decline over the next 3 years (-6% per year).

High Growth Revenue: PTN's revenue is forecast to decline over the next 3 years (-6% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Palatin Technologies performed over the past 5 years?

52.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTN has high quality earnings.

Growing Profit Margin: PTN's current net profit margins (60.9%) are higher than last year (1.2%).


Past Earnings Growth Analysis

Earnings Trend: PTN has become profitable over the past 5 years, growing earnings by 52.2% per year.

Accelerating Growth: PTN's earnings growth over the past year (10568.9%) exceeds its 5-year average (52.2% per year).

Earnings vs Industry: PTN earnings growth over the past year (10568.9%) exceeded the Biotechs industry 66.2%.


Return on Equity

High ROE: PTN's Return on Equity (40.2%) is considered outstanding.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Palatin Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: PTN's short term assets ($92.2M) exceed its short term liabilities ($1.4M).

Long Term Liabilities: PTN's short term assets ($92.2M) exceed its long term liabilities ($13.5K).


Debt to Equity History and Analysis

Debt Level: PTN is debt free.

Reducing Debt: PTN has no debt compared to 5 years ago when its debt to equity ratio was 29.9%.


Balance Sheet

Inventory Level: PTN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PTN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTN is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: PTN is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is Palatin Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate PTN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PTN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.5yrs

Average board tenure


CEO

Carl Spana (57yo)

19.7yrs

Tenure

US$2,274,411

Compensation

Dr. Carl Spana, Ph.D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief  ...


CEO Compensation Analysis

Compensation vs Market: Carl's total compensation ($USD2.27M) is above average for companies of similar size in the US market ($USD522.48K).

Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
John K. Prendergast
Co-Founder & Non-Executive Chairman19.7yrsUS$267.90k0.14% $184.0k
Carl Spana
Co-Founder19.7yrsUS$2.27m0.35% $480.6k
Arlene Morris
Independent Director4.7yrsUS$138.30k0.066% $89.7k
Robert deVeer
Independent Director21.3yrsUS$148.30k0.091% $123.9k
Alan Dunton
Independent Director8.7yrsUS$170.18k0.075% $102.1k
Anthony Manning
Independent Director2.4yrsUS$130.80k0.018% $24.6k
Raymond Rosen
Member of Female Sexual Dysfunction Expert Panel0yrsno datano data
Michael Perelman
Member of Female Sexual Dysfunction Expert Panel0yrsno datano data
J. Hull
Independent Director14.4yrsUS$140.80k0.071% $95.8k
Angela Rossetti
Independent Director6.7yrsUS$138.30k0.067% $91.5k

11.5yrs

Average Tenure

65.5yo

Average Age

Experienced Board: PTN's board of directors are seasoned and experienced ( 11.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.2%.


Top Shareholders

Company Information

Palatin Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Palatin Technologies, Inc.
  • Ticker: PTN
  • Exchange: AMEX
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$135.756m
  • Shares outstanding: 229.24m
  • Website: https://www.palatin.com

Number of Employees


Location

  • Palatin Technologies, Inc.
  • Cedar Brook Corporate Center
  • 4B Cedar Brook Drive
  • Cranbury
  • New Jersey
  • 8512
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTNAMEX (NYSE MKT LLC)YesCommon StockUSUSDOct 1993
PTNADB (Deutsche Boerse AG)YesCommon StockDEEUROct 1993
0KF3LSE (London Stock Exchange)YesCommon StockGBUSDOct 1993

Biography

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor agonist, which has completed Phase III trial for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor 1 (MCr) agonist peptide that has completed Phase I clinical trial for inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease. Further, it is involved in developing MC4r agonist peptide and small molecule for the treatment of rare genetic metabolic and obesity disorders. Additionally, the company engages in the development of PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 00:21
End of Day Share Price2020/02/21 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.